Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England.
Adult
Aged
Aged, 80 and over
Anosmia
/ epidemiology
Antibodies, Viral
/ blood
Asymptomatic Infections
/ epidemiology
COVID-19
/ blood
England
/ epidemiology
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
Male
Middle Aged
Prospective Studies
SARS-CoV-2
/ immunology
Seroepidemiologic Studies
Spike Glycoprotein, Coronavirus
/ immunology
Twins
Young Adult
Anosmia
Antibody
Asymptomatic
COVID-19
Immunity
Population
SARS-CoV-2
Seropoprevalence
UK
Journal
The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
01
10
2020
accepted:
11
10
2020
pubmed:
18
10
2020
medline:
8
1
2021
entrez:
17
10
2020
Statut:
ppublish
Résumé
Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms. We undertook enzyme linked immunosorbent assay characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged 19-86 (median age 48; 85% female). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million. We demonstrated a seroprevalence of 12% (51 participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic, and 16 (27%) were asymptomatic for core COVID-19 symptoms: fever, cough or anosmia. Specificity of anosmia for seropositivity was 95%, compared to 88% for fever cough and anosmia combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive. Seroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic throughout the study. Anosmia demonstrated the highest symptom specificity for SARS-CoV-2 antibody response. NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC.
Sections du résumé
BACKGROUND
Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms.
METHODS
We undertook enzyme linked immunosorbent assay characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged 19-86 (median age 48; 85% female). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million.
FINDINGS
We demonstrated a seroprevalence of 12% (51 participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic, and 16 (27%) were asymptomatic for core COVID-19 symptoms: fever, cough or anosmia. Specificity of anosmia for seropositivity was 95%, compared to 88% for fever cough and anosmia combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive.
INTERPRETATION
Seroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic throughout the study. Anosmia demonstrated the highest symptom specificity for SARS-CoV-2 antibody response.
FUNDING
NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC.
Identifiants
pubmed: 33068628
pii: S0163-4453(20)30653-8
doi: 10.1016/j.jinf.2020.10.011
pmc: PMC7557299
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Spike Glycoprotein, Coronavirus
0
spike glycoprotein, SARS-CoV
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
931-936Subventions
Organisme : Medical Research Council
ID : MR/S023747/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_15068
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_14105
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M016560/1
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.
Références
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
PLoS One. 2021 Sep 15;16(9):e0256813
pubmed: 34525109
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33261718
Ann Intern Med. 2021 Feb;174(2):286-287
pubmed: 33587872
Nat Med. 2020 Jul;26(7):1037-1040
pubmed: 32393804
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Twin Res Hum Genet. 2019 Dec;22(6):523-529
pubmed: 31526404
PLoS Pathog. 2020 Sep 24;16(9):e1008817
pubmed: 32970782
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Front Public Health. 2020 Sep 22;8:570543
pubmed: 33072707
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941